Development
ADMA Biologics, Inc.
ADMA
$18.54
-$0.42-2.22%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -44.25% | 117.22% | 53.72% | 72.85% | 26.53% |
| Total Depreciation and Amortization | 8.44% | 12.38% | 21.65% | 27.85% | 27.59% |
| Total Amortization of Deferred Charges | 43.19% | -26.51% | 100.73% | -16.57% | -1.85% |
| Total Other Non-Cash Items | 1,088.49% | 21.33% | 17.53% | -74.96% | 84.06% |
| Change in Net Operating Assets | 100,144.44% | 210.66% | -51.77% | -9.33% | 99.98% |
| Cash from Operations | 338.46% | 190.22% | 52.78% | 43.40% | 77.95% |
| Capital Expenditure | 68.06% | 77.62% | 77.85% | 31.58% | -1.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 62.46% | 77.62% | 77.85% | 31.58% | -1.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,822,716.09% | 100.00% | 28.57% | 99.99% | 1.14% |
| Issuance of Common Stock | -99.99% | -- | -- | -- | 20.42% |
| Repurchase of Common Stock | 83.53% | 51.49% | 27.40% | -601.20% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -15,076,900.00% | -- | -- | -- | -- |
| Cash from Financing | -162.15% | 149.23% | 175.27% | -101.38% | 16.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -144.18% | 166.50% | 60.85% | -194.04% | 209.48% |